U.S. markets closed
  • S&P Futures

    3,850.00
    +15.75 (+0.41%)
     
  • Dow Futures

    30,994.00
    +85.00 (+0.28%)
     
  • Nasdaq Futures

    13,457.75
    +96.25 (+0.72%)
     
  • Russell 2000 Futures

    2,169.10
    +5.10 (+0.24%)
     
  • Crude Oil

    52.17
    -0.10 (-0.19%)
     
  • Gold

    1,854.10
    -2.10 (-0.11%)
     
  • Silver

    25.66
    +0.10 (+0.39%)
     
  • EUR/USD

    1.2182
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • Vix

    21.91
    +0.59 (+2.77%)
     
  • GBP/USD

    1.3698
    +0.0013 (+0.10%)
     
  • USD/JPY

    103.7600
    -0.0010 (-0.00%)
     
  • BTC-USD

    33,605.73
    +816.41 (+2.49%)
     
  • CMC Crypto 200

    680.32
    +70.33 (+11.53%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,746.66
    +115.21 (+0.40%)
     

SHAREHOLDER ALERT: ICPT HPQ BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

·4 min read

NEW YORK, NY / ACCESSWIRE / December 16, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11623&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: September 28, 2019 - October 7, 2020

Allegations against ICPT include that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE: HPQ)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hp-inc-loss-submission-form-2?prid=11623&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: November 6, 2015 - June 21, 2016

Allegations against HPQ include that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.

Biogen Inc. (NASDAQ: BIIB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form?prid=11623&wire=1
Lead Plaintiff Deadline: January 12, 2021
Class Period: October 22, 2019 - November 6, 2019

Allegations against BIIB include that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/621244/SHAREHOLDER-ALERT-ICPT-HPQ-BIIB-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines